Here’s how COVID-19 vaccine guidance is changing in the U.S. For people at high risk of severe COVID-19. The process of ...

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter ...

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...

The US Food and Drug Administration will now require Covid-19 vaccines from Pfizer/BioNTech and Moderna to use expanded ...

Agency leaders said there was evidence to justify approval only for older people and those with medical conditions. Many ...

"With the COVID pandemic behind us, it is time to adopt a common-sense approach to COVID policy," a spokesperson for the FDA ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Under a new policy announced Tuesday by the Trump administration, only people age 65 and older and children or young adults ...

Federal officials unveiled a rigorous regulatory approach to future COVID vaccines that could make it harder for many people ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

Its new guidance would trade the clarity and reach of our current strategy for a confusing framework that simply doesn’t fit reality.

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.